AB Science webcast of October 16, 2025
16/10/2025 – Presentation of the AB Science webcast held on October 16, 2025
AB Science will hold a virtual conference on Thursday, October 16, 2025 from 2pm to 3pm CET to provide an update on the Phase 1 study with AB8939
14/10/2025 – The purpose of this virtual conference will be to present in more detail the initial clinical data on the combination of AB8939 + venetoclax in the first three patients with refractory and relapsed AML
Revenues for the first half of 2025 and update on AB Science’s activities
10/10/2025 – AB Science today reports its revenues for the first half of 2025 and provides an update on its activities
AB Science announces a slight delay in the publication of its 2025 half-year financial report
30/09/2025 – The Company will publish its financial report for the first half of 2025 on Friday 10 October, 2025, at the latest
AB Science announces the successful completion of a 2.55 million euros private placement
04/08/2025 – AB Science announces today the successful completion of a capital increase of a total gross amount of EUR 2.55 million subscribed by a limited number of investors
AB Science receives regulatory approval from european countries to initiate third stage of Phase I/II study combining its molecule AB8939 with venetoclax for the treatment of AML
30/07/2025 – AB Science today announced the approval of the third of four stages of the Phase I/II study with the compound AB8939 in adult patients with relapsed/refractory acute myeloid leukemia
AB Science has received approval from several European countries to initiate the confirmatory phase 3 study of masitinib in ALS
24/07/2025 – AB Science today announced that the confirmatory Phase 3 study with masitinib in amyotrophic lateral sclerosis has been authorized by the first set of European countries
AB Science announces the successful completion of a EUR 1.925 million private placement
08/07/2025 – AB Science announces today the successful completion of a capital increase of a total gross amount of EUR 1.925 million subscribed by a limited number of investors
Masitinib receives FDA and EMA authorization for confirmatory phase 3 trial in metastatic castrate-resistant prostate cancer, with biomarker-driven patient selection targeting population most likely to benefit
04/07/2025 – AB Science today announced that a confirmatory phase 3 trial of masitinib in metastatic castrate resistant prostate cancer has been authorized by FDA and EMA, with a biomarker that targets patients with less advanced metastatic disease
AB Science provides an update on the renegotiation of loan repayment terms with its financial creditors
30/06/2025 – AB Science today announced that an agreement in principle has been reached with its financial creditors to postpone by 24 months the repayment of its bank debt